Bone marrow transplantation for erythroleukemia: a case report. 1994

K Kogawa, and I Sekine, and T Masuda, and Y Takada, and S Yoshioka, and T Hirota, and M Eguchi
Department of Pediatrics, National Defense Medical College, Saitama, Japan.

A 2 year old girl was diagnosed as having erythroleukemia (EL; M6 according to the French-American-British classification). After one course of low-dose cytosine arabinoside (Ara-C), complete remission was obtained. After three courses of low-dose Ara-C for consolidation, allogeneic bone marrow transplantation was performed from HLA-identical sibling. The course of post-transplantation was uneventful. Two years after transplantation, she continues to have durable engraftment and remission. In children with EL, conventional chemotherapy appears to be inadequate for producing durable long-term disease-free survival. Bone marrow transplantation should be considered in children with EL, in cases where suitable donors are available.

UI MeSH Term Description Entries
D007621 Karyotyping Mapping of the KARYOTYPE of a cell. Karyotype Analysis Methods,Analysis Method, Karyotype,Analysis Methods, Karyotype,Karyotype Analysis Method,Karyotypings,Method, Karyotype Analysis,Methods, Karyotype Analysis
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D003561 Cytarabine A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) Ara-C,Arabinofuranosylcytosine,Arabinosylcytosine,Cytosine Arabinoside,Aracytidine,Aracytine,Cytarabine Hydrochloride,Cytonal,Cytosar,Cytosar-U,beta-Ara C,Ara C,Arabinoside, Cytosine,Cytosar U,beta Ara C
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004915 Leukemia, Erythroblastic, Acute A myeloproliferative disorder characterized by neoplastic proliferation of erythroblastic and myeloblastic elements with atypical erythroblasts and myeloblasts in the peripheral blood. Di Guglielmo's Disease,Erythremic Myelosis,Erythroblastic Leukemia, Acute,Erythroleukemia,Leukemia, Myeloid, Acute, M6,Myeloid Leukemia, Acute, M6,Di Guglielmo Disease,Acute Erythroblastic Leukemia,Acute Erythroblastic Leukemias,Di Guglielmos Disease,Disease, Di Guglielmo,Disease, Di Guglielmo's,Erythremic Myeloses,Erythroblastic Leukemias, Acute,Erythroleukemias,Leukemia, Acute Erythroblastic,Leukemias, Acute Erythroblastic,Myeloses, Erythremic,Myelosis, Erythremic
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D016026 Bone Marrow Transplantation The transference of BONE MARROW from one human or animal to another for a variety of purposes including HEMATOPOIETIC STEM CELL TRANSPLANTATION or MESENCHYMAL STEM CELL TRANSPLANTATION. Bone Marrow Cell Transplantation,Grafting, Bone Marrow,Transplantation, Bone Marrow,Transplantation, Bone Marrow Cell,Bone Marrow Grafting
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes

Related Publications

K Kogawa, and I Sekine, and T Masuda, and Y Takada, and S Yoshioka, and T Hirota, and M Eguchi
April 1978, [Rinsho ketsueki] The Japanese journal of clinical hematology,
K Kogawa, and I Sekine, and T Masuda, and Y Takada, and S Yoshioka, and T Hirota, and M Eguchi
June 1997, Zhonghua yi xue za zhi = Chinese medical journal; Free China ed,
K Kogawa, and I Sekine, and T Masuda, and Y Takada, and S Yoshioka, and T Hirota, and M Eguchi
March 1996, European journal of cancer (Oxford, England : 1990),
K Kogawa, and I Sekine, and T Masuda, and Y Takada, and S Yoshioka, and T Hirota, and M Eguchi
April 1986, Deutsche zahnarztliche Zeitschrift,
K Kogawa, and I Sekine, and T Masuda, and Y Takada, and S Yoshioka, and T Hirota, and M Eguchi
January 1995, Psychotherapy and psychosomatics,
K Kogawa, and I Sekine, and T Masuda, and Y Takada, and S Yoshioka, and T Hirota, and M Eguchi
November 2020, Transplantation proceedings,
K Kogawa, and I Sekine, and T Masuda, and Y Takada, and S Yoshioka, and T Hirota, and M Eguchi
December 2006, Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia,
K Kogawa, and I Sekine, and T Masuda, and Y Takada, and S Yoshioka, and T Hirota, and M Eguchi
January 2005, Klinika oczna,
K Kogawa, and I Sekine, and T Masuda, and Y Takada, and S Yoshioka, and T Hirota, and M Eguchi
August 1992, Transplantation proceedings,
K Kogawa, and I Sekine, and T Masuda, and Y Takada, and S Yoshioka, and T Hirota, and M Eguchi
February 2011, Zhonghua bing li xue za zhi = Chinese journal of pathology,
Copied contents to your clipboard!